NIH Webinar: A Drug Repurposing Approach for Clinical Treatment of Triple-Negative Breast Cancer

Register for a free NIH technology webinar to learn about a potential, novel treatment for Triple Negative Breast Cancer (TNBC). William Reinhold and his team at the National Cancer Institute repurposed two separate therapeutic compounds ─ acetalax and bisacodyl (both previously used as laxatives) ─ into novel treatments for TNBC. Acetalax and bisacodyl show promising results in killing TNBC cells in patient-derived xenografts (PDX) cell lines and mouse models. Attend to learn more about this technology and opportunities to help develop and commercialize it.